


**PRODUCT: SP-2509****ALTERNATE NAME:** 3-(4-morpholinylsulfonyl)-benzoic acid (2E)-2-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazide**CATALOG #:** 9446-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C<sub>19</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>5</sub>S**MOLECULAR WEIGHT:** 437.9**CAS NUMBER:** 1423715-09-6**APPEARANCE:** Off-white solid**SOLUBILITY:** DMSO (~ 25 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light**DESCRIPTION:** SP-2509 is a reversible inhibitor of Lysine-specific demethylase (LSD1) (IC<sub>50</sub> = 13 nM). It has no effect on monoamine oxidases A and B. SP2509 attenuates the binding of LSD1 to CoREST, allowing increased methylation of H3K4 and driving increased expression of p21, p27, and CCAAT/enhancer binding protein α in cultured acute myeloid leukemia (AML) cells.**REFERENCES:** Sorna, V., *et al.* (2013). *J. Med. Chem.* **56**, 9496-9508.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

Caffeic acid (Cat. No. 2303-50, 250)

Clorgyline hydrochloride (Cat. No. 2622-10, 50)

Daminozide (Cat. No. 2438-100, 500)

Disulfiram (Cat. No. 2308-10, 50)

Ebselen (Cat. No. 2169-5, 25)

GSK-J4 hydrochloride (Cat. No. 2259-1, 5)

GSK-J4 (Free base) (Cat. No. 2762-1,5)

GSK-J1 sodium (Cat. No. 2260-1, 5)

GSK-J1 (Cat. No. 2761-1,5)

Harmine (Cat. No. 2561-50, 250)

IOX1 (Cat. No. 2266-5, 25)

Jumonji HDM Inhibitor, JOB-04 (Cat. No. 2474-5, 25)

Jumonji HDM Inhibitor, PBIT (Cat. No. 2475-5, 25)

β-Lapachone (Cat. No. 2262-5, 25)

ML-324 (Cat. No. 2763-5, 25)

OG-L002 (Cat. No. 9406-5, 25)

Pargyline hydrochloride (Cat. No. 2618-500, 1000)

2,4-PDCA (Cat. No. 2304-100, 500)

Rasagiline mesylate (Cat. No. 2237-50, 250)

Tranlylcypromine hemisulfate (Cat. No. 1816-25, 100)

**USAGE:** FOR RESEARCH CH USE ONLY! Not to be used in humans